cGMP-compliant transportation conditions for a prompt therapeutic use of marrow mesenchymal stromal/stem cells

Methods Mol Biol. 2015;1283:109-22. doi: 10.1007/7651_2014_105.

Abstract

We recently described conditions for safe 18-h manufacturer-to-patient transportation of freshly harvested hBM-MSC expanded under cGMP protocols using human platelet lysate (hPL), that allowed prompt use as an advanced therapeutic medicinal product. Here we outline important considerations when comparing different transportation conditions, highlighting that although cell transportation may involve a reduction in viability, this did not undermine the ultimate bone-forming regenerative potential of the cGMP-hBM-MSC population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Culture Techniques / methods
  • Cell Culture Techniques / standards
  • Guideline Adherence*
  • Humans
  • Mesenchymal Stem Cells / cytology*
  • Specimen Handling / methods*
  • Specimen Handling / standards*
  • Transportation*